Arcus Biosciences (RCUS) Tops Q4 EPS by 22c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($0.93), $0.22 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $34 million versus the consensus estimate of $22.59 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Nortech Systems, Inc. (NSYS) Tops Q2 EPS by 11c
• Stantec (STN) Tops Q2 EPS by 47c